Abstract
Oncolytic virotherapy is an area of cancer treatment that has garnered significant attention, with various oncolytic viruses evaluated in clinical trials. In the past decade, three oncolytic viruses have received regulatory approval. The advantage of oncolytic virotherapy lie not only in the direct destruction of tumor cells by the virus but also in the stimulation of an antitumor immune response. However, there are issues in terms of application, particularly regarding the use of viruses in treatment and the fact that these therapies are primarily localized treatments. In terms of antitumor efficacy, the challenges include limited efficiency of virus delivery and dissemination, as well as the elimination of viruses by the host’s immune system. Many researchers are conducting various studies to overcome these challenges. I introduce the advancements and challenges in oncolytic virotherapy.
